Lupus Nephritis (LN) is one of the most common manifestations of systemic lupus erythematosus (SLE), affecting approximately 40% of patients with lupus. It constitutes a significant risk factor for morbidity and mortality, and it is also anticipated that 10% of patients with Lupus Nephritiswill develop end-stage kidney disease (ESKD).
DelveInsight estimates a robust Lupus Nephritis pipeline with more than 20 drugs under different phases of clinical development. Although there is a presence of many therapeutic drugs for the Lupus Nephritis treatment domain, there is still no permanent cure found for the condition.
DelveInsight offers a brand new inclusion to its newsletter edition that pivots on the Lupus Nephritis domain. The newsletter encompasses the Lupus Nephritis treatment landscape constituting the current, marketed and upcoming, novel drugs in the LN therapeutic area. Also, details of the Lupus Nephritis market, epidemiological insights, ongoing clinical trials, pipeline therapies are expected to transform the LN market in the coming decade are all covered.
Dive deep into rich insights of Lupus Nephritis latest news and happenings, mergers and collaborations, critical pharmaceuticals involved, licensing deals along with events and grand conferences taking place in the Lupus Nephritis market space.
Subscribe to our mailing list and stay informed about all the latest developments in the Autoimmune Diseases therapeutic market.
Download our Newsletter by simply filling up the form towards the right and stay in touch to learn more about our fresh offerings and services.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- Unmet needs
- R&D in the field
- Top conferences
- News flash
- Support from International organizations
- Recent Research Activities
- Market insights
- Lupus Nephritis Market Dynamics
- Collaborations and deals in the domain